FLUDARABINE PHARMACOKINETICS IN NONMYELOABLATIVE HEMATOPOIETIC CELL TRANSPLANTAT

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The overall objective of this research project is to investigate the pharmacokinetics of fludarabine in patients undergoing nonmyeloablative hematopoietic cell transplantation (HCT). Aim I will characterize pharmacokinetics of fludarabine in HCT patients at first dose and steady state. Aims II and III will investigate pharmacokinetic measures and their relationship to renal function, engraftment and neurotoxicity. Aim IV is to obtain patient DNA for pharmacokinetic studies.